Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Karyopharm Therapeutics to post earnings of ($4.21) per share and revenue of $35.12 million for the quarter. Karyopharm Therapeutics has set its FY 2025 guidance at EPS.
Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, topping analysts' consensus estimates of ($3.90) by $0.30. The company had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. On average, analysts expect Karyopharm Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Karyopharm Therapeutics Stock Down 0.8%
Shares of KPTI traded down $0.05 during trading hours on Monday, reaching $5.96. 34,556 shares of the company traded hands, compared to its average volume of 82,000. The stock has a fifty day simple moving average of $5.52 and a 200 day simple moving average of $8.94. The stock has a market capitalization of $51.10 million, a PE ratio of -5.83 and a beta of 0.33. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $17.85.
Wall Street Analyst Weigh In
Several brokerages have weighed in on KPTI. Royal Bank of Canada reiterated an "outperform" rating and issued a $45.00 price target on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. HC Wainwright upped their price objective on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a "buy" rating in a research note on Wednesday, February 26th. Finally, Robert W. Baird decreased their target price on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $57.50.
Check Out Our Latest Research Report on KPTI
About Karyopharm Therapeutics
(
Get Free Report)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Recommended Stories
Before you consider Karyopharm Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Karyopharm Therapeutics wasn't on the list.
While Karyopharm Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
